AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9395153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behaviour therapy (CBT)
Number of subjects: 99
Study 9395153 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cognitive-behaviour therapy with a serotonergic antidepressant (fluvoxamine)
Number of subjects: 99
Study 9395153 — intervention group
Group type: COMPARATOR
Intervention: Non-responders at post-treatment
Number of subjects: 99
Study 9395153 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of symptoms, motivation for treatment, and dimensional score on the PDQ-R for cluster A personality disorder
Number of subjects: 99
Study 8187446 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gold (6-9 mg auranofin by mouth daily)
Number of subjects: 46
Study 8187446 — intervention group
Group type: COMPARATOR
Intervention: Injectable gold (Solganal, aurothioglucose, 50-100 mg, intramuscularly, 2 to 4 weeks)
Number of subjects: 46
Study 3025306 — intervention group
Group type: EXPERIMENTAL
Intervention: vidarabine
Number of subjects: 59
Study 3025306 — intervention group
Group type: COMPARATOR
Intervention: acyclovir
Number of subjects: 59
Study 3025306 — intervention group
Group type: EXPERIMENTAL
Intervention: NAb
Number of subjects: 59
Study 3025306 — intervention group
Group type: EXPERIMENTAL
Intervention: LT
Number of subjects: 59
Study 3025306 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha interferon production
Number of subjects: 59
Study 3025306 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG and IgM antibody reactivity
Number of subjects: 59
Study 29145626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Treatment Advocates (TTAs) intervention with multiple visits, motivational interviewing, cessation counseling, and navigation to cessation resources
Number of subjects: 250
Study 29145626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Treatment Advocates (TTAs) intervention
Number of subjects: 250
Study 29145626 — intervention group
Group type: COMPARATOR
Intervention: Standard cessation materials and a one-time visit from a TTA providing basic counseling
Number of subjects: 250
Study 28158212 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP therapy for more than four hours per night, for more than 70% of nights
Number of subjects: 35
Study 28158212 — intervention group
Group type: EXPERIMENTAL
Intervention: nCPAP therapy (entire group)
Number of subjects: 35
Study 28158212 — intervention group
Group type: COMPARATOR
Intervention: sub-therapeutic CPAP pressure
Number of subjects: 35
Study 28158212 — intervention group
Group type: COMPARATOR
Intervention: maintenance CPAP group
Number of subjects: 35
Study 26232514 — intervention group
Group type: EXPERIMENTAL
Intervention: CCF 0.60‐0.79
Number of subjects: 2011
Study 26232514 — intervention group
Group type: EXPERIMENTAL
Intervention: CCF ≥0.80
Number of subjects: 2011
Study 21685346 — intervention group
Group type: EXPERIMENTAL
Intervention: Number sense intervention (8-week program, small-group, 30-min sessions, 3 days per week, total of 24 sessions)
Number of subjects: 121
Study 21685346 — intervention group
Group type: EXPERIMENTAL
Intervention: Number sense intervention
Number of subjects: 121
Study 21685346 — intervention group
Group type: COMPARATOR
Intervention: Business as usual contrast group
Number of subjects: 121
Study 21565487 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400mg b.i.d. in addition to palliative chemotherapy
Number of subjects: 319
Study 21565487 — intervention group
Group type: COMPARATOR
Intervention: Placebo in addition to palliative chemotherapy
Number of subjects: 319
Study 17975234 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg i.v.
Number of subjects: 120
Study 17975234 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline 2 mL i.v.)
Number of subjects: 120
Study 15916166 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/d vitamin E and 1000 mg/d vitamin C for 30 days
Number of subjects: 30
Study 15916166 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 15 days
Number of subjects: 30
Study 12351269 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2% MCT/LCT
Number of subjects: 30
Study 12351269 — intervention group
Group type: COMPARATOR
Intervention: Propofol 2% LCT
Number of subjects: 30
Study 9690396 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial 100‐microg intravenous bolus followed by a continuous 25 microg/hr octreotide infusion (group I)
Number of subjects: 36
Study 9690396 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous 25 microg/hr octreotide infusion without an initial bolus (group II)
Number of subjects: 36
Study 9690396 — intervention group
Group type: COMPARATOR
Intervention: Continuous placebo infusion (group III)
Number of subjects: 36
Study 8130043 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 22
Study 8130043 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia
Number of subjects: 22
Study 2478049 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with morphine (1.8 mg, n = 16)
Number of subjects: 64
Study 2478049 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA with oxymorphone (0.3 mg, n = 16)
Number of subjects: 64
Study 2478049 — intervention group
Group type: COMPARATOR
Intervention: PCA + BI with morphine (0.6 mg/hour, n = 16)
Number of subjects: 64
Study 2478049 — intervention group
Group type: COMPARATOR
Intervention: PCA + BI with oxymorphone (0.1 mg/hour, n = 16)
Number of subjects: 64
Study 31859967 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (four modules, carried out in four occasions)
Number of subjects: 58
Study 31859967 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not participate in educational sessions)
Number of subjects: 58
Study 29493100 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitiglinide 10 mg/voglibose 0.2 mg three times daily for 3 days
Number of subjects: 20
Study 29493100 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride 1 mg once daily for 3 days
Number of subjects: 20
Study 27607411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (methotrexate+sulfasalazine+hydroxychloroquine with prednisolone)
Number of subjects: 234
Study 27607411 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with anti-TNF induction (infliximab)
Number of subjects: 234
Study 27607411 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with placebo
Number of subjects: 234
Study 24127364 — intervention group
Group type: COMPARATOR
Intervention: CET plus placebo
Number of subjects: 750
Study 24127364 — intervention group
Group type: EXPERIMENTAL
Intervention: CET plus brivanib alaninate (BRIV)
Number of subjects: 750
Study 22584733 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel alone (PTX)
Number of subjects: 300
Study 22584733 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel alone (DTX)
Number of subjects: 300
Study 22584733 — intervention group
Group type: COMPARATOR
Intervention: Anthracycline-cyclophosphamide followed by paclitaxel (ACP)
Number of subjects: 300
Study 22584733 — intervention group
Group type: COMPARATOR
Intervention: AC followed by docetaxel (ACD)
Number of subjects: 300
Study 22584733 — intervention group
Group type: EXPERIMENTAL
Intervention: Any taxane regimen
Number of subjects: 300
Study 22584733 — intervention group
Group type: COMPARATOR
Intervention: Any regimen
Number of subjects: 300
Study 23282652 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for allergic rhinitis
Number of subjects: 0
Study 23282652 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for asthma associated with rhinitis
Number of subjects: 0
Study 23282652 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 0
Study 23282652 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) for atopic dermatitis, latex allergy, and hymenoptera hypersensitivity
Number of subjects: 0
Study 18028578 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible laryngeal mask airway
Number of subjects: 120
Study 18028578 — intervention group
Group type: COMPARATOR
Intervention: Reinforced tracheal tube
Number of subjects: 120
Study 16118294 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic soft tissue mobilisation (STM)
Number of subjects: 45
Study 16118294 — intervention group
Group type: COMPARATOR
Intervention: Classic soft tissue mobilisation (STM)
Number of subjects: 45
Study 16118294 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 12719883 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 49
Study 12719883 — intervention group
Group type: COMPARATOR
Intervention: Saline + furosemide (40 mg after hydration)
Number of subjects: 49
Study 12719883 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline + mannitol (50 g mixed with cisplatin)
Number of subjects: 49
Study 11061799 — intervention group
Group type: EXPERIMENTAL
Intervention: MMR vaccine
Number of subjects: 1162
Study 8859177 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppository (50 mg) administered once or twice daily for 4 or 8 weeks
Number of subjects: 8
Study 8859177 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppository (50 mg)
Number of subjects: 8
Study 1536727 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin 6 mg/kg body wt. per day for 3 months and tapering doses over the next 3 months
Number of subjects: 40
Study 1536727 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil at a cumulative dose of 8 mg/kg body wt.
Number of subjects: 40
Study 6097125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmenoxime (0.5 to 1 g every six hours)
Number of subjects: 41
Study 6097125 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (1 to 2 g every six hours)
Number of subjects: 41
Study 31303933 — intervention group
Group type: EXPERIMENTAL
Intervention: Postgraduate dissertations
Number of subjects: 231
Study 31303933 — intervention group
Group type: COMPARATOR
Intervention: Control group (published papers)
Number of subjects: 231
Study 31303933 — intervention group
Group type: EXPERIMENTAL
Intervention: Undergraduate dissertations
Number of subjects: 231
Study 29661873 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 0
Study 26821697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure (CP)
Number of subjects: 60
Study 26821697 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 60
Study 25461792 — intervention group
Group type: EXPERIMENTAL
Intervention: Videoconference-assisted ERP (VCT)
Number of subjects: 30
Study 25461792 — intervention group
Group type: COMPARATOR
Intervention: Self-help ERP (S-H)
Number of subjects: 30
Study 25461792 — intervention group
Group type: COMPARATOR
Intervention: Wait-list condition (W-L)
Number of subjects: 30
Study 22289129 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental report of impulsivity in first-grade girls
Number of subjects: 119
Study 22289129 — intervention group
Group type: COMPARATOR
Intervention: Conduct problems
Number of subjects: 119
Study 22289129 — intervention group
Group type: COMPARATOR
Intervention: Oppositional defiant behavior
Number of subjects: 119
Study 20846442 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Map (MM)
Number of subjects: 131
Study 20846442 — intervention group
Group type: COMPARATOR
Intervention: Standard Note-Taking (SNT)
Number of subjects: 131
Study 17704023 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA/gamma‐CD complex (660 mg EPA + 280 mg DHA/day)
Number of subjects: 42
Study 17704023 — intervention group
Group type: COMPARATOR
Intervention: Control group (capsules containing essentially no n‐3 PUFA)
Number of subjects: 42
Study 16178985 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 1000
Study 12045164 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 1.2 g orally 2 hours before vaccination
Number of subjects: 12
Study 12045164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 12045164 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intrabrachial aspirin 10 mg/min for 15 minutes
Number of subjects: 12
Study 10402690 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer perspective in social phobia
Number of subjects: 0
Study 10402690 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer perspective in agoraphobia
Number of subjects: 0
Study 10402690 — intervention group
Group type: EXPERIMENTAL
Intervention: Observer perspective in blood/injury phobia
Number of subjects: 0
Study 10402690 — intervention group
Group type: COMPARATOR
Intervention: Non-social/non-anxiety-provoking situation
Number of subjects: 0
Study 7794876 — intervention group
Group type: EXPERIMENTAL
Intervention: Foods containing added sugars
Number of subjects: 8
Study 7794876 — intervention group
Group type: COMPARATOR
Intervention: Foods containing naturally-occurring sugars
Number of subjects: 8
Study 2021561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (test group, N=17)
Number of subjects: 36
Study 2021561 — intervention group
Group type: COMPARATOR
Intervention: Routine methods (control group, N=19)
Number of subjects: 36
Study 7078985 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine (Valoron)
Number of subjects: 15
Study 7078985 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziepam (Demetrin)
Number of subjects: 15
Study 7078985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 30998551 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward walking observational training
Number of subjects: 14
Study 30998551 — intervention group
Group type: COMPARATOR
Intervention: Landscape observation + backward walking training
Number of subjects: 14
Study 29663291 — intervention group
Group type: COMPARATOR
Intervention: Apatinib (oral administration)
Number of subjects: 0
Study 29663291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27062051 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 97
Study 27062051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 27062051 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib and Placebo
Number of subjects: 97
Study 23437899 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulations of context salience and encoding strategy
Number of subjects: 0
Study 23437899 — intervention group
Group type: EXPERIMENTAL
Intervention: Context effects on pair memory
Number of subjects: 0
Study 21585410 — intervention group
Group type: EXPERIMENTAL
Intervention: 5mL midazolam
Number of subjects: 206
Study 21585410 — intervention group
Group type: COMPARATOR
Intervention: 3mL midazolam
Number of subjects: 206
Study 21585410 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine (not prefilled)
Number of subjects: 206
Study 21585410 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sedation
Number of subjects: 206
Study 18834466 — intervention group
Group type: EXPERIMENTAL
Intervention: AF ablation
Number of subjects: 0
Study 18834466 — intervention group
Group type: COMPARATOR
Intervention: SVT ablation
Number of subjects: 0
Study 18834466 — intervention group
Group type: EXPERIMENTAL
Intervention: AF ablation with recurrent AF
Number of subjects: 0
Study 17066580 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler sonography
Number of subjects: 100
Study 17066580 — intervention group
Group type: COMPARATOR
Intervention: Conventional sonography
Number of subjects: 100
Study 12706704 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent live, cold‐adapted influenza virus vaccine (CAIV‐T) co-administered with trivalent inactivated influenza virus vaccine (TVV)
Number of subjects: 2215
Study 12706704 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza virus vaccine (TVV) and placebo (TP)
Number of subjects: 2215
Study 11115157 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol‐coated liposomal doxorubicin hydrochloride (Doxil)
Number of subjects: 60
Study 9112109 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech recognition in noise
Number of subjects: 50
Study 9112109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive ability in elderly subjects
Number of subjects: 50
Study 9112109 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech recognition in noise dysfunction in elderly subjects
Number of subjects: 50
Study 9112109 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance differences between young and elderly subjects
Number of subjects: 50
Study 1318765 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (group 1, 54 volunteers) at 0, 1, and 2 months
Number of subjects: 104
Study 1318765 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (group 2, 50 volunteers) at 0, 1, and 6 months
Number of subjects: 104
Study 1318765 — intervention group
Group type: COMPARATOR
Intervention: Naturally infected subjects
Number of subjects: 104
Study 3800819 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate (0.0, 0.5, 1.0, 2.0, and 4.0 X 75 kg‐1)
Number of subjects: 20
Study 3800819 — intervention group
Group type: COMPARATOR
Intervention: Ethanol (0.082% blood alcohol level)
Number of subjects: 20
Study 29514524 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel
Number of subjects: 60
Study 29514524 — intervention group
Group type: COMPARATOR
Intervention: Onion extract gel
Number of subjects: 60
Study 26825736 — intervention group
Group type: EXPERIMENTAL
Intervention: cilnidipine
Number of subjects: 62
Study 26825736 — intervention group
Group type: COMPARATOR
Intervention: amlodipine
Number of subjects: 62
Study 24964176 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg co-administered with steady-state erythromycin in subjects with mild or moderate RI
Number of subjects: 0
Study 24964176 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg co-administered with steady-state erythromycin in subjects with moderate RI
Number of subjects: 0
Study 24964176 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban administered alone in RI subjects
Number of subjects: 0
Study 24964176 — intervention group
Group type: COMPARATOR
Intervention: Rivaroxaban co-administered with steady-state erythromycin in NRF subjects
Number of subjects: 0
Study 23234606 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (AM)
Number of subjects: 310
Study 23234606 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 310
Study 20198713 — intervention group
Group type: EXPERIMENTAL
Intervention: Pardoprunox (9‐45 mg/d, mean dose 23.8 mg/d)
Number of subjects: 139
Study 20198713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 139
Study 20198713 — intervention group
Group type: EXPERIMENTAL
Intervention: Pardoprunox
Number of subjects: 139
Study 18302208 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 102
Study 18302208 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 102
Study 18302208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy with clinical management (PHT-CM)
Number of subjects: 102
Study 18427286 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid (EACA) 5 g IV
Number of subjects: 60
Study 18427286 — intervention group
Group type: COMPARATOR
Intervention: Aprotinin 1 x 10 KIU
Number of subjects: 60
Study 15307936 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormone replacement therapy (levothyroxine)
Number of subjects: 7
Study 15307936 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 healthy subjects)
Number of subjects: 7
Study 11479247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (up to 10 mg/d)
Number of subjects: 9297
Study 11479247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9297
Study 9438110 — intervention group
Group type: EXPERIMENTAL
Intervention: Teflon piston with a shaft diameter of 0.4 mm
Number of subjects: 60
Study 9438110 — intervention group
Group type: COMPARATOR
Intervention: Teflon piston with a shaft diameter of 0.3 mm
Number of subjects: 60
Study 8106945 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE membranes
Number of subjects: 12
Study 8106945 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 12
Study 3307366 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin plus nadolol (titrated from 20 to 120 mg daily)
Number of subjects: 32
Study 3307366 — intervention group
Group type: COMPARATOR
Intervention: Digoxin plus placebo
Number of subjects: 32
Study 30661836 — intervention group
Group type: EXPERIMENTAL
Intervention: HydroVax-001 (1 mcg dose)
Number of subjects: 40
Study 30661836 — intervention group
Group type: EXPERIMENTAL
Intervention: HydroVax-001 (4 mcg dose)
Number of subjects: 40
Study 30661836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28679341 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical likelihood approach to covariate adjustment
Number of subjects: 0
Study 28679341 — intervention group
Group type: COMPARATOR
Intervention: Existing efficient adjusted estimators
Number of subjects: 0
Study 27092472 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy plus intravenous tPA administration
Number of subjects: 196
Study 25409546 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (AS-AQ)
Number of subjects: 383
Study 25409546 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 383
Study 22350679 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mcg of HFA‐BDP twice daily
Number of subjects: 16
Study 22350679 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg of HFA‐BDP twice daily
Number of subjects: 16
Study 22350679 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (25 mg/day)
Number of subjects: 16
Study 22350679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 20212073 — intervention group
Group type: COMPARATOR
Intervention: Diet intervention
Number of subjects: 385
Study 20212073 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose niacin 2000 mg plus lovastatin 40 mg
Number of subjects: 385
Study 20212073 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose niacin 1000 mg plus lovastatin 40 mg
Number of subjects: 385
Study 17707010 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin and oxybutynin
Number of subjects: 54